Wall Street analyst estimates for PureTech Health plc (PRTC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-27 | $-1.16 | ||
| 2026-04-29 | $-26.90 | $-1.94 | -1286.6% |
| 2025-08-28 | $-1.90 | $-2.04 | +6.9% |
| 2025-04-30 | $3.60 | $-2.83 | +227.2% |
| 2024-08-28 | $-1.50 | $-3.03 | +50.5% |
| 2024-04-25 | $-1.50 | $-3.25 | +53.8% |
| 2023-08-29 | $-0.90 | $-0.03 | -2900.0% |
| 2023-04-28 | $-0.78 | $0.34 | -329.4% |
Valuation Ratios
| Price / Book | 0.13 |
| EV / EBITDA | -42.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $650000 | $16.4M | $8.7M | $8.3M | $10.0M | $2.1M | $3.3M | $4.8M | $4.7M |
| Cost of Revenue | $1.6M | $71.0M | $77.4M | $85.8M | 0 | $110.5M | $152.4M | $4.9M | $3.6M | 0 |
| Gross Profit | $2.9M | -$70.4M | -$61.0M | -$77.2M | $8.3M | -$100.5M | -$136.8M | -$1.6M | $1.3M | $4.7M |
| Research & Development | $41.2M | $71.7M | $57.3M | $65.2M | $61.2M | $81.5M | $116.1M | $96.2M | $54.3M | $45.7M |
| Selling, General & Admin | $37.2M | $46.3M | $24.4M | $34.9M | $26.5M | $30.8M | $35.7M | $48.4M | $27.5M | $20.7M |
| Operating Expenses | $78.4M | $116.1M | $120.4M | $144.1M | $127.9M | $160.3M | $61.0M | $54.6M | $140.4M | $103.2M |
| Operating Income | -$73.9M | -$115.4M | -$104.0M | -$135.4M | -$119.5M | -$150.3M | -$197.8M | -$146.2M | -$136.1M | -$98.5M |
| EBITDA | -$74.8M | -$40.8M | -$65.3M | $487.8M | $62.7M | $26.7M | -$188.9M | -$11.6M | $37.4M | -$61.8M |
| Interest Expense | $6.8M | $10.2M | $14.8M | $4.1M | $2.9M | $4.7M | $4.0M | $13.5M | $10.0M | $45.8M |
| Pre-tax Income | -$83.2M | -$70.7M | -$68.4M | $478.5M | $19.0M | -$59.0M | -$92.8M | -$36.1M | $23.8M | -$110.9M |
| Income Tax | -$1.6M | -$14000 | $2.2M | $112.4M | $14.4M | $3.8M | -$55.7M | $30.5M | -$4.0M | -$842000 |
| Net Income | -$48.8M | $30.9M | -$43.7M | $421.1M | $6.0M | -$60.6M | -$50.4M | -$65.7M | $53.5M | -$109.7M |
| EPS | $-2.10 | $1.10 | $-1.60 | $14.40 | $0.20 | $-2.10 | $-1.80 | $-2.40 | $2.00 | $-46.00 |
| EPS (Diluted) | $-2.10 | $1.10 | $-1.60 | $14.40 | $0.20 | $-2.10 | $-1.80 | $-2.40 | $2.00 | $-46.00 |
| Shares Outstanding (Diluted) | $23.0M | $23.9M | $27.4M | $29.2M | $29.3M | $28.7M | $28.5M | $27.6M | $27.0M | $2.4M |
Price
| Price | $17.38 |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLYM · GNTA · INBX · IVA · KROS · SLN · TARS
Explore sector: Healthcare · Biotechnology
More sections of PRTC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks